The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...

In a clinical trial, the personalized mRNA vaccine reduced the two-year risk of recurrence and death .

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage ...

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/Getty. A ...

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising ...

Skepticism about the government’s pandemic response is one thing. Writing off mRNA vaccine technology is another.

The conversation has already turned to how melanoma specialists should adopt the medicine — and how widely these novel vaccines can be deployed.

Merck and Moderna’s new personalized cancer vaccine paired with the standard of care reduced the risk of recurrence and death ...

A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way ...

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...